ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,272.46
0.82%
Dow Jones
39,134.76
0.77%
Gold vs US Dollar
2,358.355
1.24%
Brent Oil
85.005
0.37%
Bitcoin
64,986.99
0.03%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tempest Therpeutics Inc (TPST)

  7. Tempest Therpeutics Inc (TPST) News

Tempest Therpeutics (TPST)

Tempest Therpeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TPST
DateTimeSourceHeadlineSymbolCompany
20/06/202413:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TPSTTempest Therpeutics Inc
20/06/202413:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TPSTTempest Therpeutics Inc
20/06/202413:00GlobeNewswire Inc.Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control ArmNASDAQ:TPSTTempest Therpeutics Inc
18/06/202423:22GlobeNewswire Inc.Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular CarcinomaNASDAQ:TPSTTempest Therpeutics Inc
14/06/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TPSTTempest Therpeutics Inc
14/06/202421:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TPSTTempest Therpeutics Inc
07/06/202409:30GlobeNewswire Inc.Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TPSTTempest Therpeutics Inc
21/05/202413:00GlobeNewswire Inc.Tempest to Participate in Upcoming Investor ConferencesNASDAQ:TPSTTempest Therpeutics Inc
13/05/202421:54Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TPSTTempest Therpeutics Inc
09/05/202421:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TPSTTempest Therpeutics Inc
09/05/202421:29GlobeNewswire Inc.Tempest Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TPSTTempest Therpeutics Inc
09/05/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TPSTTempest Therpeutics Inc
26/04/202421:05GlobeNewswire Inc.Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TPSTTempest Therpeutics Inc
09/04/202413:00GlobeNewswire Inc.Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingNASDAQ:TPSTTempest Therpeutics Inc
04/04/202413:00GlobeNewswire Inc.Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsNASDAQ:TPSTTempest Therpeutics Inc
19/03/202420:25GlobeNewswire Inc.Tempest Reports Year End 2023 Financial Results and Provides Business UpdateNASDAQ:TPSTTempest Therpeutics Inc
12/03/202412:00GlobeNewswire Inc.Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer TypesNASDAQ:TPSTTempest Therpeutics Inc
05/03/202421:30GlobeNewswire Inc.Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual MeetingNASDAQ:TPSTTempest Therpeutics Inc
26/02/202413:00GlobeNewswire Inc.Tempest to Present at the 44th Annual TD Cowen Healthcare ConferenceNASDAQ:TPSTTempest Therpeutics Inc
14/02/202423:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TPSTTempest Therpeutics Inc
14/02/202419:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TPSTTempest Therpeutics Inc
08/02/202422:41Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TPSTTempest Therpeutics Inc
02/02/202421:30GlobeNewswire Inc.Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TPSTTempest Therpeutics Inc
05/01/202421:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TPSTTempest Therpeutics Inc
05/01/202421:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TPSTTempest Therpeutics Inc
05/01/202421:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TPSTTempest Therpeutics Inc
05/01/202421:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TPSTTempest Therpeutics Inc
05/01/202421:05GlobeNewswire Inc.Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TPSTTempest Therpeutics Inc
01/12/202321:15GlobeNewswire Inc.Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TPSTTempest Therpeutics Inc
20/11/202313:00GlobeNewswire Inc.Tempest to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:TPSTTempest Therpeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TPST

Your Recent History

LSE
AAZ
Anglo Asian Mining
LSE
GKP
Gulf Keystone Petroleum
LSE
BIRD
Blackbird
LSE
POS
Plexus
LSE
THG
Thg
LSE
ENET
Ethernity Networks
LSE
GDR
Genedrive
LSE
YOU
Yougov
LSE
POLX
Polarean Imaging
LSE
TERN
Tern
LSE
SRSP
Sirius Petroleum
LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
VAST
Vast Resources
LSE
OCDO
Ocado
LSE
EEE
Empire Metals
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved